Authors: Sarah L Greig Gillian M Keating
Publish Date: 2015/06/24
Volume: 75, Issue: 11, Pages: 1269-1280
Abstract
Oral naltrexone extendedrelease/bupropion extendedrelease naltrexone ER/bupropion ER Contrave® Mysimba™ is available as an adjunct to a reducedcalorie diet and increased physical activity in adults with an initial body mass index BMI of ≥30 kg/m2 ie obese or a BMI of ≥27 kg/m2 ie overweight in the presence of at least one bodyweightrelated comorbidity such as type 2 diabetes mellitus hypertension or dyslipidaemia In 56week phase III trials in these patient populations oral naltrexone ER/bupropion ER 32/360 mg/day was significantly more effective than placebo with regard to percentage bodyweight reductions from baseline and the proportion of patients who achieved bodyweight reductions of ≥5 and ≥10 Significantly greater improvements in several cardiometabolic risk factors were also observed with naltrexone ER/bupropion ER versus placebo as well as greater improvements in glycated haemoglobin levels in obese or overweight adults with type 2 diabetes Naltrexone ER/bupropion ER was generally well tolerated in phase III trials with nausea being the most common adverse event Thus naltrexone ER/bupropion ER 32/360 mg/day as an adjunct to a reducedcalorie diet and increased physical activity is an effective and well tolerated option for chronic bodyweight management in obese adults or overweight adults with at least one bodyweightrelated comorbidityThe preparation of this review was not supported by any external funding During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on this article Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit Sarah Greig and Gillian Keating are salaried employees of Adis/Springer
Keywords: